Actively Recruiting
Phase 1 Study of BC2027 Given by IV Infusion to Evaluate Safety, Tolerability, and Early Effects in Adults With Advanced Solid Tumors
Led by Biocity Biopharmaceutics Co., Ltd. · Updated on 2026-01-26
180
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics PK, and early anticancer activity of BC2027 in patients with advanced solid malignancies. This phase IaIb open-label study includes patients with advanced tumors who have failed or are intolerant to standard therapies. The study aims to understand how BC2027 behaves in the body and assess its potential effects against cancers expressing the GPC3 protein. The study has two parts Part 1 is a dose escalation phase where BC2027 is given intravenously at increasing doses to find a suitable dose for further study. Dosing schedules include every two weeks Q2W in a 28-day cycle and every three weeks Q3W in a 21-day cycle. Part 2 is a dose expansion phase treating patients with GPC3-positive tumors such as non-small cell lung cancer, hepatocellular carcinoma, and other solid cancers at the recommended dose from Part 1. Participants will undergo screening within 28 days before starting treatment, followed by treatment cycles as scheduled. Safety follow-up occurs 45 days after the last dose, with survival follow-up every 12 weeks until death. Researchers will monitor dose limiting toxicities, safety, tolerability, and preliminary antitumor activity over an average of 2 years. Assessments include tumor measurements, organ function tests, and monitoring for adverse effects throughout the study.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
Research Team
F
Feng Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here